DUPIXENT

sanofi-aventis canada inc🇨🇦 Health Canada

Approval Id: dc0dd6dc8941bdcd
Drug Approval Canada Name: DUPIXENT
Product Name: DUPIXENT
Status: Marketed
Status Date: 2022-06-23
Original Market Date: 2022-06-23
Din: 02524252
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Prescription , Schedule D
Ahfs: 84:06.28
Atc Original: D11AH05 DUPILUMAB
Atc Name: d 11 ah 05
Aig Number: 0159790002
Company Name: sanofi-aventis canada inc
Company Address: 1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4

DUPILUMAB

200 MG / 1.14 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

dc0dd6dc8941bdcd

Type

Standard